Qureator is excited to announce a new research collaboration with SillaJen Inc. to evaluate combination immunotherapy using BAL0891, a dual TTK/PLK1 inhibitor, with PD-1 immune checkpoint inhibitors. The study will leverage Qureator’s advanced 3D Tumor Immune Microenvironment (TIME) model, which replicates human-relevant tumor biology using patient-derived cells.
The collaboration will assess immunomodulatory effects and combination synergies in challenging cancers including TNBC, RCC, gastric cancer, and colorectal cancer. This joint effort aims to identify optimal therapeutic strategies and expand indications for BAL0891 through high-fidelity preclinical modeling.
We are proud to partner with SillaJen in accelerating novel oncology treatments and driving more predictive, patient-specific immunotherapy development. Together, we are one step closer to reshaping the future of cancer care with human-relevant science.
https://www.pharmnews.com/news/articleView.html?idxno=245629